News
-
-
PRESS RELEASE
Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution
Hardman & Co Research provides analysis on Shield Therapeutics (STX) focusing on successful execution. Shield progressing well with sales traction and cost control, aiming for cashflow-break even in 2H'25 -
-
-
-
PRESS RELEASE
Hardman & Co Q&A on H&T Group (HAT) | 1H24 results curate's egg of good and bad
Hardman & Co analyst interview provides insights into H&T Group's 1H'24 results, highlighting positive pledge lending demand and retail sales growth. Mark Thomas discusses the company's future outlook and key risks -
-
-
-
PRESS RELEASE
Hardman & Co Q&A on H&T Group (HAT) | Putting H&T Group’s pawnbroking business into a global perspective
Hardman & Co analyst Mark Thomas provides a thorough analysis of H&T Group's pawnbroking business in a global perspective, discussing market size, cultural acceptance, valuation, and investment potential